DMKJ
David M. Knott Jr Portfolio holdings
AUM
$221M
This Quarter Return
+12.82%
1 Year Return
+22.52%
3 Year Return
+148.91%
5 Year Return
–
10 Year Return
–
AUM
$221M
AUM Growth
+$221M
(+4.1%)
Cap. Flow
-$7.42M
Cap. Flow
% of AUM
-3.36%
Top 10 Holdings %
Top 10 Hldgs %
71.57%
Holding
93
New
9
Increased
15
Reduced
13
Closed
8
Top Buys
| 1 |
BridgeBio Pharma
BBIO
|
$3.45M |
| 2 |
LENZ
LENZ Therapeutics
LENZ
|
$2.4M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$2.11M |
| 4 |
Alkermes
ALKS
|
$1.4M |
| 5 |
Liquidia Corp
LQDA
|
$1.12M |
Top Sells
| 1 |
Pfizer
PFE
|
$4.36M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$3.12M |
| 3 |
Janus Henderson AAA CLO ETF
JAAA
|
$2.87M |
| 4 |
Ardelyx
ARDX
|
$2.42M |
| 5 |
OmniAb
OABI
|
$2.36M |
Sector Composition
| 1 | Healthcare | 31.49% |
| 2 | Materials | 24.07% |
| 3 | Financials | 19.36% |
| 4 | Communication Services | 9.05% |
| 5 | Industrials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Calumet Specialty Products
CLMT
$1.42B
| $51.6M | 23.39% |
3,275,231
-21,963
| -0.7% | -$346K |
|
2
Apollo Global Management
APO
$77B
| $31.9M | 14.47% |
225,000
| – | – |
|
|
3
Janus Henderson AAA CLO ETF
JAAA
$24.8B
| $25.1M | 11.39% |
495,254
-56,509
| -10% | -$2.87M |
|
4
Alphabet (Google) Class C
GOOG
$2.55T
| $19.9M | 9.02% |
112,220
| – | – |
|
5
JPMorgan Chase
JPM
$821B
| $6.08M | 2.76% |
20,985
| – | – |
|
|
VRNA
6
Verona Pharma
VRNA
$9.17B
| $5.2M | 2.36% |
55,000
-33,000
| -38% | -$3.12M |
|
7
Xeris Biopharma Holdings
XERS
$1.27B
| $4.95M | 2.24% |
1,060,000
-50,000
| -5% | -$234K |
|
8
DocGo
DCGO
$151M
| $4.82M | 2.19% |
3,070,850
| – | – |
|
9
Protagonist Therapeutics
PTGX
$3.66B
| $4.42M | 2% |
80,000
+4,000
| +5% | +$221K |
|
10
Travere Therapeutics
TVTX
$1.64B
| $3.85M | 1.74% |
260,000
+32,000
| +14% | +$474K |
|
11
Catalyst Pharmaceutical
CPRX
$2.51B
| $3.82M | 1.73% |
176,000
-36,000
| -17% | -$781K |
|
|
AVDL
12
Avadel Pharmaceuticals
AVDL
$1.45B
| $3.77M | 1.71% |
426,000
| – | – |
|
|
13
BridgeBio Pharma
BBIO
$9.83B
| $3.45M | 1.57% |
+80,000
| New | +$3.45M |
|
|
14
Syndax Pharmaceuticals
SNDX
$1.4B
| $3.3M | 1.5% |
352,778
+224,778
| +176% | +$2.11M |
|
15
BioCryst Pharmaceuticals
BCRX
$1.76B
| $2.98M | 1.35% |
332,625
-127,375
| -28% | -$1.14M |
|
|
INZY
16
DELISTED
Inozyme Pharma
INZY
| $2.66M | 1.21% |
666,204
| – | – |
|
|
ESGR
17
DELISTED
Enstar Group
ESGR
| $2.52M | 1.14% |
7,500
| – | – |
|
|
LENZ
18
LENZ Therapeutics
LENZ
$1.11B
| $2.4M | 1.09% |
+82,000
| New | +$2.4M |
|
19
CSX Corp
CSX
$60B
| $2.28M | 1.04% |
70,000
| – | – |
|
20
AllianceBernstein
AB
$4.33B
| $1.96M | 0.89% |
48,000
| – | – |
|
21
Ultragenyx Pharmaceutical
RARE
$3.08B
| $1.89M | 0.86% |
52,000
+4,000
| +8% | +$145K |
|
|
22
Pfizer
PFE
$141B
| $1.81M | 0.82% |
74,537
-180,000
| -71% | -$4.36M |
|
23
Arcellx
ACLX
$3.89B
| $1.69M | 0.77% |
25,700
+10,700
| +71% | +$705K |
|
24
AtriCure
ATRC
$1.8B
| $1.52M | 0.69% |
46,443
+21,823
| +89% | +$715K |
|
|
TECX
25
Tectonic Therapeutic, Inc. Common Stock
TECX
$313M
| $1.47M | 0.67% |
74,000
+34,000
| +85% | +$676K |
|